As of 06 Nov 2026 13:32 UTC. Status is always as stated in the latest recorded notice; the sources do not publish resolution, so nothing on this page says a medicine is back — see methodology.
Presentations, as stated in the latest recorded notice
Each line is re-expressed from MSN/2026/004 (28 Jan 2026): the product named, the status the source stated, and the expected-back phrase kept as written. Not the source's sentence, and not an observation of stock.
| Presentation | Status, as stated | Expected back, as stated | Stated in |
|---|---|---|---|
| Oxybutynin (Kentera®) 3.9mg/24hours transdermal patchesaffected product · inferred from phrasing | Out of stock, as stated | late-February 2026precision: late in the month · window end 28 Feb 2026, derived from “late-February 2026” | notice of 28 Jan 2026 |
| Oxybutynin 5mg and 10mg modified-release tabletsnamed by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 28 Jan 2026 |
| Oxybutynin 2.5mg/5ml and 5mg/5ml oral solution sugar freenamed by the source as remaining available · inferred from phrasing | Stated as available | — not stated for this line | notice of 28 Jan 2026 |
| Oxybutynin 2.5mg and 5mg tabletsnamed by the source as remaining available · inferred from phrasing | Stated as available; cannot support an uplift in demand | — not stated for this line | notice of 28 Jan 2026 |
| Alternative anticholinergic/non-anticholinergic agents for urinary incontinenceclass-level statement by the source, not a named product · inferred from phrasing | Stated as available | — not stated for this line | notice of 28 Jan 2026 |
Protocol in force
No Serious Shortage Protocol matched to this name is in force on the NHSBSA register. Matching is by name until identifier coding lands.
Named in the source as remaining available
- Oxybutynin 5mg and 10mg modified-release tablets — named by the source as remaining available (inferred from phrasing)
- Oxybutynin 2.5mg/5ml and 5mg/5ml oral solution sugar free — named by the source as remaining available (inferred from phrasing)
- Oxybutynin 2.5mg and 5mg tablets — named by the source as remaining available (inferred from phrasing)
Only names the source itself listed, as it listed them (source post ↗). No substitution, dosing or counselling advice is given here or implied.
Identifiers — Oxybutynin
BNF chemical and SNOMED identifiers from NHSBSA Prescription Cost Analysis (Open Government Licence), matched by name (presentation name), confidence 0.90 — grouping under review where marked Release Jul 2026.
BNF SNOMED mapping, NHSBSA Copyright 2026; Prescription Cost Analysis (PCA) Monthly Administrative Data, NHSBSA Copyright 2026. This information is licenced under the terms of the Open Government Licence.
History
Notified short 4 times on record since 2022 — a recurring shortage spanning 3.9 years. We record when a shortage is declared, not when stock returns — the source doesn't publish that. An update sharing a reference counts as one episode.
| Issued | Notice | Kind | Tier | Reference |
|---|---|---|---|---|
| 28 Jan 2026 | Medicine Supply Notification: Oxybutynin (Kentera® ) 3.9mg/24hours transdermal patches | Supply notification | Tier 2 | MSN/2026/004 |
| 18 Dec 2023 | Medicine Supply Notification: Oxybutynin 5mg modified-release tablets | Supply notification | Tier 2 | MSN/2023/116 |
| 24 Apr 2023 | Medicine Supply Notification: Oxybutynin 5mg modified-release tablets | Supply notification | Tier 2 | MSN/2023/048 |
| 16 Mar 2022 | Medicine Supply Notification: Oxybutynin (Kentera®) 3.9mg/24hour transdermal patches. | Supply notification | Tier 2 | MSN/2022/027 |
Also recorded under
Bracketed names seen in this medicine's notice titles: kentera. Grouping is by the head name in each title; brand and generic names may still sit on separate pages until identifier coding refines it — see the A–Z.
Scotland — separate record
NHS Scotland issues its own Medicine Supply Alert Notices. These match this medicine's name; they are shown beside, never added to, the England record.
- MSAN(2026)5 Oxybutynin (Kentera®) 3.9mg/24hours transdermal patches · issued 30 Jan 2026 · valid until late-February 2026, as stated · matched by name PDF ↗